New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Max Neeman International Sets Up Research Team for Nutraceutical Studies

Max Neeman International, a leading Indian CRO, expands its list of services with the formation of an exclusive team to conduct studies on Nutraceuticals. There is an emerging trend in the Nutraceuticals industry (also known as the "Fast Moving Healthcare Goods") and India is one of the fastest growing markets because of world class CROs, R&D facilities, qualified human resources and varied raw materials. These factors, along with special dietary needs of the elderly, are the driving force behind the development of Nutraceuticals and need for CRO collaboration.

The Max Neeman Nutraceutical studies team consists of specialized and experienced endocrinologists, nutritionists and dietitians with sound experience in executing such studies. The team has conducted trials in the areas of pediatric dietary supplements and preoperative infusion of Omega 3 Fatty Acids.

Max Neeman is now structured to serve the special interests of the Nutraceutical industry and is India's leading CRO for Drug Development, Device studies, Data Management, Medical Writing and Electronic Data Capture for Phase I-IV Studies.

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 22 cities with 5 regional offices. Contact Donald Swankie, Vice President of Business Development for more information ([email protected]/+1.919.424.3345).

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.